Results 51 to 60 of 158 matches
Category 6 - PATHOLOGY SERVICES
73346 - Additional Information
Testing of a pregnant patient whose carrier status for pathogenic cystic fibrosis transmembrane conductance regulator variants, as well as their reproductive partner carrier status is unknown, for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus, in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73350 applies.
The fetus must have ultrasonic findings of echogenic gut, with unknown familial cystic fibrosis transmembrane conductance regulator variants.
Fee: $500.00 Benefit: 75% = $375.00 85% = $425.00
(See para PN.7.3, PN.7.16 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73347 - Additional Information
Testing of a prospective parent for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the risk of their fetus having pathogenic cystic fibrosis transmembrane conductance regulator variants. This is indicated when the fetus has ultrasonic evidence of echogenic gut when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73348, or 73349 applies.
Fee: $500.00 Benefit: 75% = $375.00 85% = $425.00
(See para PN.7.3, PN.7.16 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73348 - Additional Information
Testing of a patient with a laboratory-established family history of pathogenic cystic fibrosis transmembrane conductance regulator variants, for the purpose of determining whether the patient is an asymptomatic genetic carrier of the pathogenic cystic fibrosis transmembrane conductance regulator variants that have been laboratory established in the family history, not being a service associated with a service to which item 73345, 73347, or 73349 applies.
The patient must have a positive family history, confirmed by laboratory findings of pathogenic cystic fibrosis transmembrane conductance regulator variants, with a personal risk of being a heterozygous genetic carrier of at least 6%. (This includes family relatedness of: parents, children, full-siblings, half-siblings, grand-parents, grandchildren, aunts, uncles, first cousins, and first cousins once-removed, but excludes relatedness of second cousins or more distant relationships).
Fee: $250.00 Benefit: 75% = $187.50 85% = $212.50
(See para PN.7.3, PN.7.16 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73349 - Additional Information
Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the reproductive risk of the patient with their reproductive partner because their reproductive partner is already known to have pathogenic cystic fibrosis transmembrane conductance regulator variants requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73347, or 73348 applies.
Fee: $500.00 Benefit: 75% = $375.00 85% = $425.00
(See para PN.7.3, PN.7.16 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73350 - Additional Information
Testing of a pregnant patient, where one or both prospective parents are known to be a genetic carrier of pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus, when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73346 applies.
The fetus must be at 25% or more risk of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder because of known familial cystic fibrosis transmembrane conductance regulator variants.
Fee: $250.00 Benefit: 75% = $187.50 85% = $212.50
(See para PN.7.3, PN.7.16 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73351 - Additional Information
A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non-small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled.
Fee: $397.35 Benefit: 75% = $298.05 85% = $337.75
Category 6 - PATHOLOGY SERVICES
73352 - Additional Information
Characterisation of germline variants causing familial hypercholesterolaemia (which must include the LDLR, PCSK9 and APOB genes), requested by a specialist or consultant physician, for a patient:
(a) for whom no familial mutation has been identified; and
(b) who has any of the following:
(i) a Dutch Lipid Clinic Network score of at least 6;
(ii) an LDL-cholesterol level of at least 6.5 mmol/L in the absence of secondary causes;
(iii) an LDL-cholesterol level of between 5.0 and 6.5 mmol/L with signs of premature or accelerated atherogenesis
Applicable only once per lifetime
Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,101.30
Category 6 - PATHOLOGY SERVICES
73353 - Additional Information
Detection of a familial mutation for a patient who has a first- or second-degree relative with a documented pathogenic germline gene variant for familial hypercholesterolaemia
Applicable only once per lifetime
Fee: $400.00 Benefit: 75% = $300.00 85% = $340.00
Category 6 - PATHOLOGY SERVICES
73354 - Additional Information
Characterisation of germline gene variants, including copy number variation, in the MLH1, MSH2, MSH6, PMS2 and EPCAM genes, requested by a specialist or consultant physician, for:
(a) a patient with suspected Lynch syndrome following immunohistochemical examination of neoplastic tissue that has demonstrated loss of expression of one or more mismatch repair proteins; or
(b) a patient:
(i) who has endometrial cancer; and
(ii) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having Lynch syndrome, on the basis of clinical and family history criteria
Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,101.30
Category 6 - PATHOLOGY SERVICES
73355 - Additional Information
Characterisation of germline gene variants, including copy number variation, in the APC and MUTYH genes, requested by a specialist or consultant physician, for a patient:
(a) who has adenomatous polyposis; and
(b) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having either of the following, on the basis of clinical and family history criteria:
(i) familial adenomatous polyposis;
(ii) MUTYH-associated polyposis
Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,101.30
Results 51 to 60 of 158 matches
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change